Summit Therapeutics EBITDA 2015-2024 | SMMT

Summit Therapeutics EBITDA for the quarter ending September 30, 2024 was $-0.058B, a 185.23% increase year-over-year.

  • Summit Therapeutics 2023 EBITDA was -0.608B, a 773.3% increase from 2022.
  • Summit Therapeutics 2022 EBITDA was -0.07B, a 16.91% decline from 2021.
  • Summit Therapeutics 2021 EBITDA was -0.084B, a 63.57% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Summit Therapeutics EBITDA 2015-2024 | SMMT

  • Summit Therapeutics 2023 EBITDA was -0.608B, a 773.3% increase from 2022.
  • Summit Therapeutics 2022 EBITDA was -0.07B, a 16.91% decline from 2021.
  • Summit Therapeutics 2021 EBITDA was -0.084B, a 63.57% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.